Antidepressants' Link to New-Onset Diabetes

Published Online: Friday, December 14, 2012
Follow Pharmacy_Times:
Long-term use of antidepressants may increase the risk of diabetes in elderly patients, according to a study published online on November 23, 2012, by the Journal of Diabetes.

The study looked at data from the Medicare Current Beneficiary Survey of elderly Medicare beneficiaries. Diabetes data were collected over a 3-year period. Researchers examined the association between antidepressant use, depression, and new-onset diabetes. The data were adjusted for demographic, socioeconomic, and lifestyle risk factors.

Participants who used antidepressants during the 3-year period were 50% more likely to have new-onset diabetes than patients who did not use antidepressants. Patients who were diagnosed with any depression were twice as likely to develop diabetes than those without depression. However, there was no significant correlation between antidepressant use and new onset diabetes in patients with diagnosed depression.

The researchers conclude that depression may independently increase the risk of diabetes. They also suggest that long-term use of antidepressants without a depression diagnosis increases the risk for diabetes. The researchers state that if the study results are repeated with additional research, they could impact clinical decisionmaking.

Related Articles
The FDA announced today that it will permit the marketing of a mobile medical app that will help patients with diabetes share data from a continuous glucose monitor with other individuals.
Leaders of Senate and House committees with health care jurisdiction should hold oversight hearings to examine the issues that plagued approximately 50,000 beneficiaries who are covered by Aetna Medicare Part D drug plans.
Community pharmacists are most concerned about below-cost reimbursement for certain generic drugs as well as exclusionary Medicare drug plans according to a survey conducted by the National Community Pharmacists Association that asked its members to help identify the organization’s 2015 priorities.
The introduction of sodium glucose transporter 2 inhibitors has marked a turning point in the management of patients with both type 1 and type 2 diabetes.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$